Somewhere in a clinic in Melbourne in the mid-2000s, a peptide that everyone thought would dethrone the leading obesity drugs quietly failed its biggest exam. That peptide was AOD-9604, and almost twenty years later it is back, sold by wellness clinics and online vendors as a “fat-burning” injection. The marketing is loud. The human evidence is much quieter, and a lot more honest than the ads let on.
If you are trying to separate the hype from the data on AOD-9604, this is the part most pages skip: a drug company spent years and over 900 trial subjects on this molecule, and then walked away. Here is exactly what the research shows, what it does not show, and where AOD-9604 legally stands today.
What is the actual evidence that AOD-9604 causes fat loss?
The honest answer: AOD-9604 produced modest weight loss in one early human trial, then failed to beat placebo in its larger pivotal trial, and pharmaceutical development was halted in 2007. Animal studies show clear fat reduction, but that effect did not reliably translate to humans. No regulator (FDA, EMA, or Australia’s TGA) has approved it for weight loss.
That sentence carries the whole story, so let us unpack how researchers got there.
Where did AOD-9604 come from?
AOD-9604 is a synthetic fragment of human growth hormone (hGH). Specifically, it copies the tail end of the hGH molecule (residues 177 to 191, with an added tyrosine), the region scientists identified as carrying the fat-reducing activity of growth hormone without the parts that raise blood sugar or spike IGF-1. The Australian biotech Metabolic Pharmaceuticals developed it under the theory that you could isolate the “burn fat” signal of hGH and leave the risky metabolic baggage behind ([news-medical.net](https://www.news-medical.net/news/2004/12/16/6878.aspx)).
In rodents, the idea worked. AOD-9604 stimulated lipolysis (fat breakdown) and inhibited lipogenesis (fat storage) without affecting growth or insulin sensitivity. That is genuinely interesting biology. The problem, as so often happens, is that mice are not people.
What did the human clinical trials actually find?
This is where most “AOD-9604 results” articles quietly stop reading the data.
The optimistic number you see everywhere comes from a 12-week Phase IIa trial of roughly 300 obese adults run by Metabolic Pharmaceuticals. In that study, the 1 mg daily oral dose group lost about 2.8 kg on average, compared with about 0.8 kg in the placebo group, roughly triple the placebo result ([news-medical.net](https://www.news-medical.net/news/2004/12/16/6878.aspx)). The findings were later published in the peer-reviewed literature by Herd and colleagues as a randomized, double-blind, placebo-controlled multicenter study ([University of Melbourne](https://findanexpert.unimelb.edu.au/scholarlywork/1828647-the-effect-of-aod9604-on-weight-loss-in-obese-adults–results-of-a-randomized–double-blind–placebo-controlled–multicenter-study)).
For context, losing under 3 kg over three months is real but modest. It is a fraction of what today’s GLP-1 medications produce. Still, for a peptide that appeared to be very safe, it looked promising enough to advance.
Then came the pivotal Phase IIb trial, sometimes called the OPTIONS study. It was bigger (536 obese adults, BMI 30 to 45), longer (24 weeks), and tested several oral doses against placebo. And it failed to show a statistically significant weight-loss advantage for AOD-9604 over placebo. Notably, the earlier weight-loss signal disappeared once an intensive diet and exercise regimen was layered on top, meaning the peptide could not clearly outperform lifestyle change alone. Metabolic Pharmaceuticals halted the obesity drug development program in 2007 ([BioSpace](https://www.biospace.com/metabolic-pharmaceuticals-s-obesity-trial-update-first-100-subjects-complete-the-phase-2b-trial-of-aod9604)).
That is the part the supplement and clinic marketing almost never mentions. The bigger, better-controlled trial is the one that counts more, and it came up empty for fat loss.
Is AOD-9604 at least safe?
Safety is the strongest part of AOD-9604’s record, and it is worth giving credit where it is due. Across roughly six human trials involving around 900 participants, AOD-9604 showed a tolerability profile close to placebo: no meaningful IGF-1 elevation, no disruption of blood glucose, and no immunogenic response in the studied populations. A dedicated safety and tolerability analysis of the hexadecapeptide in humans was published by Stier and colleagues in the Journal of Endocrinology and Metabolism ([jofem.org](https://www.jofem.org/index.php/jofem/article/view/157/194)).
Here is the critical distinction a lot of buyers miss: “well tolerated in trials” is not the same as “proven to work,” and it is not the same as “safe as sold today.” Almost all of that safety data comes from an oral tablet formulation studied under controlled conditions roughly 20 years ago. The injectable, research-grade AOD-9604 sold online now is a different delivery method from unregulated suppliers, with no equivalent long-term human safety dossier behind it.
So is AOD-9604 FDA approved for weight loss?
No. This is the single most misrepresented fact about the peptide.
In 2014 the FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status as a food ingredient. Marketers love to quote this because it contains the letters “FDA.” But GRAS speaks only to ingredient safety in food, not to drug efficacy, and absolutely not to approval as a weight-loss treatment. AOD-9604 is not FDA-approved for any medical indication ([thepeptidelist.com](https://thepeptidelist.com/articles/aod-9604-guide)).
The compounding situation has also tightened. AOD-9604 was at one point nominated for the FDA’s list of bulk drug substances that compounding pharmacies could use, but it was reviewed and ultimately did not secure a place on the approved list, leaving its availability through legitimate compounding channels restricted ([FDA briefing document](https://www.fda.gov/media/183584/download)). Translation: much of what circulates is grey-market “research use only” material, not a clinic-grade approved medicine.
If you want to understand how peptides like this fit into the broader landscape of growth-hormone-derived compounds, our overview at peptides explained gives the fuller picture.
Who is actually using it, and does it live up to the marketing?
In practice, AOD-9604 today lives mostly in the wellness and “biohacking” world: med-spas, longevity clinics, and online peptide vendors marketing it for stubborn fat, body recomposition, and sometimes joint or recovery benefits (the recovery claims rest largely on preclinical and small-scale data, not robust human efficacy trials).
What the evidence supports saying is narrow but fair: AOD-9604 is a growth-hormone fragment with a clean short-term safety signal and, at best, a modest and inconsistent fat-loss effect in humans that did not survive its pivotal trial. What the evidence does not support is the common pitch that it is a powerful, proven fat-loss injection. The drug company that knew this molecule best stopped developing it precisely because it was not potent enough to compete as an obesity medicine.
If your goal is meaningful fat loss, the comparison is unflattering. Established lifestyle approaches and approved medications have far stronger evidence bases. AOD-9604 is, at this stage, an interesting failed drug candidate enjoying a second life on the supplement market, not a breakthrough.
This article is for general information only and is not medical advice. AOD-9604 is not approved for weight loss, and you should consult a qualified clinician before using any peptide or weight-loss compound.
Frequently asked questions
Does AOD-9604 really burn fat in humans?
Only modestly and inconsistently. One 12-week trial showed about 2.8 kg of weight loss on the 1 mg dose versus 0.8 kg on placebo, but the larger, longer pivotal Phase IIb trial found no significant advantage over placebo, and development was halted in 2007.
Is AOD-9604 FDA approved?
No. It received GRAS (food ingredient safety) status in 2014, which is frequently misrepresented as approval. It is not FDA-approved as a drug for weight loss or any other medical use.
How does AOD-9604 compare to GLP-1 drugs like semaglutide?
It is not in the same league. GLP-1 medications produce far larger, well-documented weight loss in clinical trials, while AOD-9604 produced only small effects that failed to reach significance in its pivotal study.
Is AOD-9604 safe?
In roughly six trials with about 900 participants, the oral form showed a placebo-like tolerability profile with no IGF-1 or glucose disruption reported. However, that data is around two decades old and based on an oral tablet, not the injectable grey-market product sold today, which lacks equivalent long-term human safety data.
Why did Metabolic Pharmaceuticals stop developing AOD-9604?
Because its pivotal 536-subject Phase IIb obesity trial did not show statistically significant weight loss versus placebo, especially once diet and exercise were added. Without reproducible efficacy, the obesity program was discontinued in 2007.
